SCHEMBL334893

SCHEMBL334893

COC(=O)CC1(N2CCCC2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
CYP2D6 P10635 7/20 0.50
ALDH1A1 P00352 3/20 0.50
OPRM1 P35372 5/20 0.48
SIGMAR1 Q99720 5/20 0.48
CYP3A4 P08684 2/20 0.48
USP2 O75604 1/20 0.48
MAPK1 P28482 1/20 0.48
OPRL1 P41146 2/20 0.45
CHRM2 P08172 1/20 0.45
CHRM3 P20309 1/20 0.45
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
ADAM17 P78536 1/20 0.45
NPFFR1 Q9GZQ6 1/20 0.45
NPFFR2 Q9Y5X5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2694056 0.82 CYP2D6 (0.54) TSHRCYP2D6ALDH1A1CYP3A4USP2
SCHEMBL26667185 0.80 MEN1 (0.53) TSHRCYP2D6ALDH1A1OPRM1CYP3A4
SCHEMBL6706472 0.79 TSHR (0.70) TSHRCYP2D6ALDH1A1CYP3A4USP2
SCHEMBL28278741 0.77 CYP2D6 (0.47) TSHRCYP2D6ALDH1A1OPRM1SIGMAR1
SCHEMBL4032706 0.77 TSHR (0.57) TSHRCYP2D6ALDH1A1CYP3A4USP2
SCHEMBL334862 0.76 TSHR (0.56) TSHRCYP2D6ALDH1A1OPRM1SIGMAR1
SCHEMBL4594010 0.75 CYP2D6 (0.47) TSHRCYP2D6ALDH1A1CYP3A4MMP1
SCHEMBL9043624 0.74 KCNH2 (0.48) TSHR
SCHEMBL16051787 0.74 CYP2D6 (0.46) TSHRCYP2D6ALDH1A1CYP3A4USP2
SCHEMBL572327 0.74 ALDH1A1 (0.62) CYP2D6ALDH1A1SIGMAR1CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
EP-1939189-A1 DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG TSHR 189/4885CYP2D6 135/4885ALDH1A1 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.